Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Psilocybin Clear all
Recruiting Phase 1 Interventional

Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

NCT07506395
View directory record Official record
Conditions
PTSD
Interventions
Psilocybin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 89 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 7, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

NCT04739865
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Jun 7, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Frontline Clinician Psilocybin Study

NCT05163496
View directory record Official record
Conditions
Burnout, Caregiver, Burnout, Professional, COVID-19, Depression, Post Traumatic Stress Disorder, Moral Injury
Interventions
Psilocybin (Usona Institute), Active placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Results available

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

NCT02950467
View directory record Official record
Conditions
Distress, Depression, Grief
Interventions
Psilocybin, Modified brief Supportive Expressive Group Therapy
Drug · Behavioral
Lead sponsor
Joshua Woolley
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Jun 7, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

NCT04656301
View directory record Official record
Conditions
Body Dysmorphic Disorders
Interventions
Psilocybin
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Jun 7, 2026, 4:26 AM EDT
Active, not recruiting Phase 1 Interventional

Effects of Repeated Psilocybin Dosing in OCD

NCT05370911
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 7, 2026, 4:26 AM EDT
Not yet recruiting Early Phase 1 Interventional

Psilocybin as a Treatment for Chronic Pain in Smokers

NCT07118332
View directory record Official record
Conditions
Smokers With Chronic Pain
Interventions
Psilocybin (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Recruiting Phase 2 Interventional

Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

NCT06405607
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Dependence, Alcohol Abuse
Interventions
Psilocybin, Ketamine
Drug
Lead sponsor
University of Iowa
Other
Eligibility
21 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

NCT07306364
View directory record Official record
Conditions
Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin
Interventions
Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

NCT07360301
View directory record Official record
Conditions
Well-Being, Psychological, Psychedelic Experiences
Interventions
Psilocybin, Saline Placebo, Clonidine
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 7, 2026, 4:26 AM EDT
Not yet recruiting Phase 1 Interventional

Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study

NCT06988319
View directory record Official record
Conditions
Chronic Pelvic Pain
Interventions
Psilocybin (Usona Institute)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Recruiting Phase 2 Interventional

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

NCT06706232
View directory record Official record
Conditions
Bipolar II Disorder, Depression, Bipolar, Suicidality
Interventions
Psilocybin, Therapeutic Support
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Terminated No phase listed Observational

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

NCT04353921
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
No intervention will be administered as part of this study.
Other
Lead sponsor
Usona Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lauderhill, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 7, 2026, 4:26 AM EDT
Completed Phase 1 Interventional

Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain

NCT05506982
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Psilocybin, Psychotherapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
26 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Completed Not applicable Interventional

Low-Income Group Psilocybin Assisted Therapy for Depression

NCT06372197
View directory record Official record
Conditions
Depression
Interventions
Psilocybin
Drug
Lead sponsor
Matthew Hicks
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Enrolling by invitation Phase 1 Interventional

Psilocybin With Intracranial Neural Sensing

NCT06919640
View directory record Official record
Conditions
Chronic Pain
Interventions
Psilocybin
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin Therapy for Chronic Low Back Pain

NCT05351541
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Psilocybin therapy with Zolpidem and Modafinil, Psilocybin therapy with Zolpidem, Psilocybin therapy with Modafinil, Psilocybin therapy with Placebo
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
25 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 7, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

NCT05312151
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Rockville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Recruiting Phase 1 Interventional

Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

NCT07347405
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin 10 mg, Psilocybin 20 mg, Psilocybin 30 mg
Drug
Lead sponsor
Francisco A Moreno
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 7, 2026, 4:26 AM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder

NCT07296094
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 7, 2026, 4:26 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Psilocybin for PTSD

NCT06407635
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Psilocybin, Trauma-focused psychotherapy, Standard psychological support
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Recruiting Phase 1 Interventional

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

NCT06989957
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Psilocybin, MDMA
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jun 7, 2026, 4:26 AM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

NCT06200155
View directory record Official record
Conditions
Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer
Interventions
Psilocybin, Niacin
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 7, 2026, 4:26 AM EDT
Completed Phase 1 Interventional

Effects of Psilocybin in Post-Treatment Lyme Disease

NCT05305105
View directory record Official record
Conditions
Post-Treatment Lyme Disease, Chronic Lyme Disease, Lyme Disease, Chronic
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jun 7, 2026, 4:26 AM EDT